Bank of Japan keeps policy rate steady while raising inflation forecast on Iran war worries
The decision to keep rates steady came in a split 6-3 vote, and was in line with Reuters-polled analysts’ estimates.
CATL declines nearly 7% as the Chinese battery maker unveils $5 billion share placement
Shares of Contemporary Amperex Technology (CATL) declined nearly 7% after the EV battery giant unveiled plans for a roughly $5 billion equity placement in Hong Kong.
BYD draws EU scrutiny over labor abuse allegations at Hungary factory
BYD has come under scrutiny from European lawmakers after a watchdog report alleged harsh working conditions at its Hungary plant.
CNBC Daily Open: Investors look past warning signs to send stock markets soaring
From stagflation warnings and stalled Iran talks to rising oil prices, red lights are everywhere.
U.S. oil hovers near $100 on report Trump dissatisfied with Iran’s proposal to open Hormuz
Oil prices rose as investors parsed fresh signals from U.S.-Iran negotiations, with uncertainty over a potential de-escalation keeping markets on edge.
Asia-Pacific markets trade mostly lower as investors assess latest U.S.-Iran signals
Asia-Pacific markets traded mixed Tuesday as investors weighed the latest updates over U.S.-Iran negotiations.
S&P 500 pulls back from record Tuesday, Nasdaq closes lower as chip stocks sell off: Live updates
The S&P 500 fell on Tuesday, weighed down by a report that pointed to weakness in OpenAI as well as a rise in oil prices.
CNBC’s The China Connection newsletter: AI is moving into the physical world — fast
From cars to robots, industries across China are seeing AI expand from cloud-based systems into devices.
Judge in Musk v. Altman seats nine-person jury. Opening arguments start Tuesday
The Musk v. Altman trial kicked off at a federal courthouse in Oakland, California, with jury selection followed by opening arguments.
Pharma bets a little-known form of cholesterol will underpin its next blockbuster heart drugs
Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology.
